tqb2223
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 6, 2023 (NCT05894421)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- LAG3INHIBITOR
LAG3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06649656 | Phase 1 | Nov 30, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06320080 | Phase 1 | Apr 30, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05894421 | Phase 1 | Jun 6, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 3 | 3 | 1 | 2023 |
1 organizations
Page 1 / 1